解读大麻和大麻素在神经疾病中的治疗潜力
Mayur B Kale1, Mohit D Umare1, Nitu L Wankhede1
1Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra, India.
Current pharmaceutical design
|October 16, 2024
概括
大麻sativa显示神经保护性质,通过大麻素受体CB1和CB2起作用. 需要进一步的研究来优化大麻素激动剂在神经系统疾病的临床使用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 植物化学 植物化学
背景情况:
- 大麻sativa具有长期的医学和娱乐用途的历史.
- 最近的研究强调了大麻成分的神经保护潜力.
- 内分泌系统,包括CB1和CB2受体,调解这些效应.
研究的目的:
- 探索大麻及其成分的神经保护性质.
- 了解大麻素受体 (CB1和CB2) 在神经保护中的作用.
- 确定大麻素受体激动剂临床应用的挑战和机遇.
主要方法:
- 关于大麻,大麻素和神经保护的最新科学文献的综述.
- 分析涉及动物实验模型的研究.
- 检查大麻素和内分泌系统之间的相互作用.
主要成果:
- 大麻表现出显著的神经保护作用,特别明显在动物模型中.
- 大麻素通过G蛋白结合受体 (GPCRs) 发挥其神经保护作用,特别是CB1和CB2.
- 大麻素受体激动剂的精确机制和最佳应用需要进一步阐明.
结论:
- 大麻素显示出对神经系统疾病有前途的神经保护能力.
- 需要有针对性的方法才能有效地利用大麻素的治疗潜力.
- 导航受体特异性和临床适用性对于未来基于大麻素的疗法至关重要.
相关概念视频
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
166
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
166
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
203
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
203
Brain Imaging
216
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
216
Disorders of the Nervous Tissue
1.1K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators
338
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
338
The Blood-brain Barrier
46.9K
Overview
46.9K


